GlassScriptPhysician profile
Heather Hathy
NPI 1881650596
$2,475.16
in general payments reported to CMS, 2019-2025
12 companies · $235 in 2025
The $235 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $587 · 2022: $400 · 2023: $611 · 2024: $643 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,436 · Education: $52.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,436.16 |
| Education | $52.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $693.11 | 2021-2025 | Entyvio |
| Abbvie INC. | $623.15 | 2022-2025 | |
| Janssen Biotech, INC. | $573.08 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Janssen Scientific Affairs, LLC | $120.77 | 2021 | |
| Gilead Sciences, INC. | $113.65 | 2021-2022 | |
| Celltrion USA INC. | $97.13 | 2024-2025 | Zymfentra, Vegzelma |
| Lilly USA, LLC | $83.92 | 2024-2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $40.67 | 2024 | |
| Merck Sharp & Dohme LLC | $38.29 | 2023-2024 | Dificid |
| Celgene Corporation | $33.49 | 2023 | Zeposia |
| Aimmune Therapeutics, INC. | $32.60 | 2023-2024 | |
| Ardelyx, INC. | $25.30 | 2023 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Hathy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.